Drug Trial Radar · NCT06383403
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid.
Last checked: Nov 20, 2026Latest source record: Jul 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
92
Actual
Start
Jul 9, 2024
Primary completion
Jun 16, 2026
Study completion Jun 16, 2026
Sponsor
- Lead sponsor
- IpsenIndustry
- Sponsor type
- Industry
- First posted
- Apr 25, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The participants in this study will have confirmed PBC with inadequate response or intolerance to Ursodeoxycholic acid (UDCA), which is a medication used in the management and treatment of cholestatic liver disease. Primary biliary cholangitis is a slowly progressive disease characterised by damage of the bile ducts in the liver, leading to a build-up of bile acids which causes further damage. The liver damage in PBC may lead to scarring (cirrhosis). PBC may also be associated with multiple symptoms. Many patients with PBC may require a liver transplant or may die if the disease progresses and a liver transplant is not done. This study will compare a daily dose of elafibranor (the study drug) to a daily dose of placebo (a dummy treatment). The main aim of this study is to determine if elafibranor is better than placebo in reducing ALP levels to a normal value. High ALP levels in the blood can indicate liver disease. There will be three periods in this study: A screening period (up to 8 weeks) to assess whether the participant can take part; a treatment period (up to 52 weeks) where eligible participants will be grouped as per their blood ALP levels and randomly assigned to either receive elafibranor or placebo, and a follow-up period (4 weeks) where participants' health will be monitored. Participants will be twice as likely to receive elafibranor than placebo (2:1 ratio). Participants will undergo blood sampling, urine collections, physical examinations, clinical evaluations, electrocardiograms (ECG: recording of the electrical activity of heart), ultrasound examinations (a noninvasive test that passes a probe over skin to look at the bladder, urinary tract, and liver), and Fibroscan® examinations (a noninvasive test that passes a probe on skin to measure stiffness of the liver). They will also be asked to fill in questionnaires. Each participant will be in this study for up to 64 weeks (15 months).
Conditions
- Primary Biliary Cholangitis
Interventions
ElafibranorDrug
Round and orange film coated tablet of 80 mg.
PlaceboOther
Round and orange film coated tablet of placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of participants with normalisation of Alkaline Phosphate (ALP) LevelsTime frame: At Week 52
Locations
60 sites in 10 countries. Site status is shown where the registry gives one.
Southern California Research Center
Coronado, California
Topgraphy Health, Inc.
Los Angeles, California
University of California, Davis
Sacramento, California
Stanford University Medical Center
Stanford, California
Peak Gastroenterology Associates
Colorado Springs, Colorado
Rocky Mountain Gastroenterology
Littleton, Colorado
International Center for Research
Tampa, Florida
Delta Research Partners, LLC
West Monroe, Louisiana
University of Michigan Health System
Ann Arbor, Michigan
Huron Gastroenterology Associates - Center for Digestive Care
Ypsilanti, Michigan
South Denver Gastroenterology,P.C.
Englewood, New Jersey
Southwest Gastroenterology Associates, PC (SWGA)
Albuquerque, New Mexico
Northwell Health Center for Liver Disease and Transplantation
Manhasset, New York
Charlotte Gastroenterology & Hepatology, PLLC
Charlotte, North Carolina
Coastal Research Institute
Fayetteville, North Carolina
Gastroenterology Center of the Midsouth
Cordova, Tennessee
Methodist Transplant Physicians
Dallas, Texas
American Research Corporation at The Texas Liver Institute
San Antonio, Texas
American Research Corporation
San Antonio, Texas
Velocity Liver Institute NW
Seattle, Washington
Hepato-Gastroenterologie HK, s.r.o.
Hradec Králové, Czechia
Artroscan
Ostrava, Czechia
Research Site s.r.o.
Pilsen, Czechia
Institute for Clinical and Experimental Medicine - IKEM
Prague, Czechia
Clinique Pasteur
Toulouse, France
Universitatsklinikum Heidelberg
Heidelberg, Germany
Gastroenterologsiche Studiengesellschaft Herne
Hemer, Germany
EUGASTRO GmbH
Leipzig, Germany
Universitaetsklinikum Muenster
Münster, Germany
Ospedale Policlinico San Martino - IRCCS
Genova, Italy
Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone
Palermo, Italy
Azienda Ospedaliero Universitaria Pisana
Pisa, Italy
IRCCS Istituto clinico humanitas - Humanitas Mirasole spa
Rozzano, Italy
Krakowskie Centrum Medyczne Sp.z.o.o - FutureMeds
Krakow, Poland
FutureMeds Warszawa Centrum
Warsaw, Poland
Cluj County Clinical Emergency Hospital
Cluj-Napoca, Romania
Gastromedica Srl
Iași, Romania
Korea University Ansan Hospital
Ansan-si, South Korea
Keimyung University Dongsan Hospital
Daegu, South Korea
Kyungpook National University Hospital (KNUH)
Daegu, South Korea
Showing 40 of 60 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.